PharmAla Welcomes New Advisory Team Member
PharmAla Biotech Holdings Inc. is thrilled to announce a new partnership that promises to enhance its growth strategy. The biotechnology firm, which focuses on the development of LaNeo™ MDMA and other MDXX class molecules, has signed an advisory agreement with Mr. Matthew Azrieli. Mr. Azrieli is not just a seasoned advisor; he is also a dedicated shareholder of PharmAla, bringing both insight and investment to the table.
The Role of Matthew Azrieli
Nick Kadysh, CEO of PharmAla, expressed his enthusiasm for this new addition, stating, “Having come to know Matthew well over the past number of months, I believe he will be able to significantly help PharmAla in a number of our developing markets.” Mr. Azrieli is expected to play a pivotal role in elevating PharmAla’s Clinical Trials business in the United States, alongside other important markets.
Performance-Based Advisory Agreement
As part of this agreement, Mr. Azrieli will have the opportunity to earn up to 1 million Performance Share Units. These units will be awarded based on the achievement of specific corporate goals across three key categories: media advisory, market development, and investment advisory. This structured approach ensures that both PharmAla and Mr. Azrieli are aligned in their commitment to advancing the company's ambitious objectives.
Investor Engagement through Webinar
Upcoming Webinar Announcement
PharmAla will also engage investors through an upcoming Webinar, scheduled to take place on February 6, 2025, at 4:30 PM Eastern Time. This event will feature presentations from both Nicholas Kadysh, CEO, and Will Avery, CFO, who will delve into the latest financial results and strategic plans for the year ahead. It’s an excellent opportunity for stakeholders to get insights directly from the leadership team.
Details of the Webinar
This engaging session will cover:
- The latest financial outcomes of PharmAla
- Goals and strategies for upcoming projects
- Opportunities for stakeholder involvement in the company’s journey
It is a must-attend for anyone interested in the current state and future of PharmAla.
About PharmAla
PharmAla Biotech Holdings Inc. operates at the forefront of the biotechnology sector, committed to the research, development, and manufacturing of MDXX class molecules like MDMA. Established with a purpose, the company aims to streamline the availability of clinical-grade MDMA for both trials and commercial use, while also innovating new drugs within this category. What sets PharmAla apart is its unique position as the only firm provisioning clinical-grade MDMA for patient treatment outside of clinical trials. The company’s research and development team has successfully concluded proof-of-concept studies on various IP families, leading with ALA-002 as its flagship drug candidate.
Contact Information
For any inquiries, reach out to:
Nicholas Kadysh
Chief Executive Officer
PharmAla Biotech Holdings Inc.
Email: press@PharmAla.ca
Phone: 1-855-444-6362
Website: www.PharmAla.ca
Frequently Asked Questions
What is PharmAla focusing on?
PharmAla is dedicated to the research and development of MDXX class molecules, particularly MDMA, to support clinical trials and patient treatments.
Who is Matthew Azrieli?
Matthew Azrieli is a shareholder and advisor to PharmAla, ideally positioned to help the company expand its clinical trials and market development efforts.
What is the significance of the advisory agreement?
The advisory agreement will facilitate PharmAla's growth in key markets by leveraging Mr. Azrieli's expertise and connections.
When will the investor webinar occur?
The webinar will take place on February 6, 2025, at 4:30 PM Eastern Time, providing critical insights into the company's strategies.
How can I contact PharmAla for more information?
You can reach PharmAla’s CEO, Nicholas Kadysh, directly via email at press@PharmAla.ca or through their website.
